^
Association details:
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
Imatinib...and second-generation TKIs (dasatinib...nilotinib...and bosutinib...) are all appropriate options for first-line TKI therapy for patients with CP-CML across all risk scores.